Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 17/20 | 0.62 |
| ▸ | MMP2 | P08253 | 17/20 | 0.62 |
| ▸ | MMP9 | P14780 | 17/20 | 0.62 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6022945 | 1.00 | MMP1 (0.62) | MMP1MMP2MMP9MAOBKDM1A | |
| SCHEMBL6023357 | 0.90 | KDM1A (0.57) | MMP1MMP2MMP9MAOBKDM1A | |
| SCHEMBL6023356 | 0.90 | KDM1A (0.57) | MMP1MMP2MMP9MAOBKDM1A | |
| SCHEMBL6022727 | 0.81 | KDM1A (0.60) | MMP1MMP2MMP9KDM1AMEN1 | |
| SCHEMBL6022726 | 0.81 | KDM1A (0.60) | MMP1MMP2MMP9KDM1AMEN1 | |
| SCHEMBL6022688 | 0.81 | MMP1 (0.59) | MMP1MMP2MMP9MAOB | |
| SCHEMBL6022690 | 0.81 | MMP1 (0.59) | MMP1MMP2MMP9MAOB | |
| SCHEMBL28316655 | 0.78 | MMP1 (1.00) | MMP1MMP2MMP9MAOB | |
| SCHEMBL6022720 | 0.76 | KDM1A (0.54) | MMP1MMP2MMP9MAOBKDM1A | |
| SCHEMBL6022715 | 0.76 | KDM1A (0.54) | MMP1MMP2MMP9MAOBKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2003-08-28 | — | — | US | claimed |
| US-7078407-B2 | 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-07-18 | — | — | US | disclosed |
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162789-A1 | 4-Hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them | HTT, PARK7, NQO1 | MMP1 2333/4885MMP2 1455/4885MMP9 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.